We are proposing a placebo-controlled pilot study of selegiline versus placebo for nicotine dependent smokers (N=30) with depressive symptoms. There is evidence that catecholamines have an important role in the rewarding and withdrawal effects of tobacco smoking, and monoamine oxidase inhibitors (MAOIs) which augment catecholamine (i.e. dopamine, norepinephrine) function may be helpful in attenuating nicotine craving and withdrawal symptoms in nicotine dependent smokers. Thus, the selective MAO-B inhibitor selegiline may be helpful as a pharmacologic adjunct for smoking cessation. The proposed study would be a 6 week trial in nicotine-dependent smokers which will compare selegiline (10 mg daily; n=15) versus placebo (n=15) treatments on smoking cessation outcomes. Subjects would be inducted onto 10 mg/day of selegiline (5 mg po bid) or matching placebo (twice daily) over a two week period prior to the """"""""quit date"""""""" at the beginning of Week 1. All subjects would receive brief weekly sessions of smoking cessation counseling consistent with AHCPR smoking cessation guidelines. The primary outcome measures include 1 week post-quit (Week 2) and endpoint (Week 6) smoking abstinence rates, and continuous smoking abstinence during the last four weeks of the trial. Secondary outcomes measures include treatment retention, depressive symptoms, nicotine withdrawal symptoms, weight change, plasma cotinine levels, expired breath carbon monoxide (CO) levels and urinary catecholamine excretion. Data analyses to compare groups will focus of an intention-to-treat sample and will utilize Chi square 2x2 contingency tables for smoking abstinence rates, repeated measures analysis of variance (ANOVA) models for continuous outcome measures (i.e. depression and nicotine withdrawal ratings, CC, plasma cotinine and urinary catecholamines) and Kaplan-Meir survival analysis for treatment retention. Results from this pilot study would be used to calculate an effect size for planning a larger controlled trial if results from this pilot study appear promising. We predict that selegiline will be superior to placebo for smoking cessation in nicotine dependent smokers on both primary and secondary outcome measures.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Yale University
New Haven
United States
Zip Code
Geha, Paul; Cecchi, Guillermo; Todd Constable, R et al. (2017) Reorganization of brain connectivity in obesity. Hum Brain Mapp 38:1403-1420
Roberts, Walter; Verplaetse, Terril L; Moore, Kelly et al. (2017) Effects of varenicline on alcohol self-administration and craving in drinkers with depressive symptoms. J Psychopharmacol 31:906-914
Corbin, William R; Papova, Anna; Morean, Meghan E et al. (2015) Integrating acquired preparedness and dual process models of risk for heavy drinking and related problems. Psychol Addict Behav 29:864-74
Smith, Megan V; Ramsay, Christina; Mazure, Carolyn M (2014) Understanding disparities in subpopulations of women who smoke. Curr Addict Rep 1:69-74
Avery, Naomi; Kenny, Anne M; Kleppinger, Alison et al. (2014) Effects of varenicline, nicotine or placebo on depressive symptoms in postmenopausal smokers. Am J Addict 23:459-65
Morean, Meghan E; DeMartini, Kelly S; Leeman, Robert F et al. (2014) Psychometrically improved, abbreviated versions of three classic measures of impulsivity and self-control. Psychol Assess 26:1003-20
Geha, Paul Y; Aschenbrenner, Katja; Felsted, Jennifer et al. (2013) Altered hypothalamic response to food in smokers. Am J Clin Nutr 97:15-22
King, Andrea C; Cao, Dingcai; Zhang, Lingjiao et al. (2013) Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial. Biol Psychiatry 73:924-30
Duncan, Lindsay R; Latimer, Amy E; Pomery, Elizabeth et al. (2013) Testing messages to encourage discussion of clinical trials among cancer survivors and their physicians: examining monitoring style and message detail. J Cancer Educ 28:119-26
Cosgrove, Kelly P; Esterlis, Irina; McKee, Sherry A et al. (2012) Sex differences in availability of ?2*-nicotinic acetylcholine receptors in recently abstinent tobacco smokers. Arch Gen Psychiatry 69:418-27

Showing the most recent 10 out of 96 publications